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Abstract We have recently reported increased survival of 
dopaminergic substantia nigra neurons by inhibition of phospho- 
diesterase type IV enzymes. As a first step to unravel the involve- 
ment of PDE IV subtypes in this process, we isolated phospho- 
diesterase type IV cDNAs from human substantia nigra. One 
isolated partial cDNA done was most homologous to the partially 
cloned rat and human PDE IV-C isogene. Distribution analysis 
revealed that the enzyme is expressed in various tissues but not 
in cells of the immune system. Isolation of the full-length human 
PDE IV-C isogene cDNA and expression in a PDE-deficient 
yeast strain resulted in functional complementation of the yeast 
heat shock response. Inhibition of the enzymatic activity by rol- 
ipram characterized this enzyme as a typical type IV phospho- 
diesterase. 
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not bFGF or IGF-I,  prevented the cultured neurons from de- 
generation and protected them from the dopaminergic neuro- 
toxin MPP + [12]. In a previous tudy with inhibitors for differ- 
ent phosphodiesterase subtypes we found, that PDE type IV 
specific inhibitors also increased the survival of dopaminergic 
neurons in primary cell culture and protected mice from the 
action of the neurotoxin MPTP [13,14]. 
In order to characterize the PDE IV subtypes involved in that 
process we isolated PDE IV cDNAs from a human substantia 
nigra cDNA library. One of the subtypes we found in this tissue 
had previously only been described as a short partial DNA 
fragment. We have now cloned and characterized the full- 
length cDNA. After expression in yeast the recombinant pro- 
tein displayed cAMP-specific activity and was sensitive to rol- 
ipram. The spatial expression of this gene was distinct from 
other known human PDE IV genes [15,16,17,18]. 
2. Materials and methods 
I. Introduction 
Cyclic nucleotide phosphodiesterases (PDEs) regulate the 
cellular concentration of cyclic nucleotides by converting 
cAMP or cGMP to the non-cyclic 5'-NMP [1]. The PDE en- 
zyme family can be divided into 7 subfamilies or classes [2,3], 
characterized by their substrate affinity and specificity and their 
sensitivity to specific inhibitors [1,4,5] and activators. The sub- 
families are Ca2+/Calmodulin-dependent PDEs (PDE I), cGMP 
stimulated PDEs (PDE II), cGMP inhibited PDEs (PDE 1II), 
cAMP-specific rolipram sensitive PDEs (PDE IV), cGMP spe- 
cific PDEs (PDE V), photoreceptor PDEs (PDE VI), and high 
affinity cAMP-specific rolipram-insensitive PDEs (PDE VII). 
For all the families, multiple related genes as well as different 
mRNA splice forms create a basis for variable control of cyclic 
nucleotide concentration i  different cells and subcellular com- 
partments [6,7]. 
One interesting family with respect o therapeutic applica- 
tions is PDE IV. Inhibitors of this enzyme class may be benefi- 
cial in asthma [8] and other inflammatory diseases [9] as well 
as in diseases of the CNS like depression [10] or multiinfarct 
dementia [11]. Recently, we demonstrated that cyclic AMP 
stimulated the dopamine uptake and development of 
mesencephalic dopaminergic neurons in primary cell cultures 
[12]. In addition, an elevated intracellular level of cAMP, but 
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2.1. Oligonucleotides 
PE 1: 5'-GTCCAAACACATGACCCTCCTGGCTGACCTG-3'; 
PE 2." 5'-GCAGGAGGGAGCTGATTGCTGGATGAAG-3'; PE 3." 
5'-TCAGAGCTGGCGCTTATGTAC-3'; PE 4: 5'-CCGTATGCTT- 
GTCACACAT-3'; PE 5." 5'-TCAAGCTGCTGCAGCAGAG-3'; PE 
6: 5'-GAGTCCTTCCTGTACCGCTCA-3'; PE 7." 5'-GACTGGA- 
GCCTGCATAATCCG-3'; PE 8: 5'-AGGTCAAAGCGCCTGC- 
AGGAGG-3'; PE 9: 5'-GCCAGTCTGCGGACCGTT-3'; PE 10." 5'- 
CAGCAATGCCCTAGGAGCAGC- 3'. 
2.2. Cloning of PDE IV  cDNA 
To isolate PDE IV isogenes expressed in the substantia nigra, we 
designed the 30 bp oligonucleotide PE 1 which was complementary to 
the highly conserved catalytic domain of all published rat and human 
PDE IV isogenes. With this oligonucleotide probe we screened three 
million independent clones of a commercial 2-Zap human substantia 
nigra cDNA library (Stratagene) using standard procedures. DNA 
sequencing was performed with the T7 sequencing kit (Pharmacia). 
Using RT-PCR as described below, we found that SH-SY5Y neuro- 
blastoma cells contain mRNA of the particular PDE isogene detected 
by PE1. To isolate a full-length cDNA clone we extracted mRNA from 
SH-SY5Y cells, cDNA was prepared from 3/lg poly(A) ÷ mRNA using 
the Amersham cDNA kit. The size selected cDNA (> 1.5 kb) was cloned 
into a modified pBluescript vector as described by Foguet et al. [19]. 
25 pools, each containing 4 × 105 independent clones with an average 
insert size of 2 kb, were obtained after transformation into the E. coli 
strain MC 1061 by electroporation (Gene Pulser, Bio-Rad). From each 
pool, 0.5 pg DNA was used for a PCR analysis which specifically 
detected the cDNA clone isolated from the sustantia nigra library. 
Three positive pools were then plated and the clones isolated by stand- 
ard filter hybridization [20] using oligonucleotide PE 1 as probe. 
To extend the 5' end, double-stranded SH-SY5Y cDNA was synthe- 
sized with the primer PE 4. After circularization of the cDNA with 
T4-DNA ligase, sequential inverse PCRs [21,22] were performed with 
the nested primer pairs PE 2/PE 3 and PE 2/PE 5. In an additional 
extension step, inverse PCR was performed using cDNA created with 
the primer PE 2. Nested primer pairs in this process were PE 6/PE 7, 
PE 8/PE 9, and PE 8/PE 10. The DNA fragments obtained were cloned 
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into pUC 18 and sequenced with the T7 sequencing kit from Pharmacia. 
The DNASIS and PROSIS programs (Hitachi) were used for sequence 
analysis. 
2.3. Distribution analysis 
A Northern blot (Clontech) with 2 ,ug poly(A) ÷ RNA from different 
human tissues was hybridized with a PDE IV-C specific riboprobe 
(derived from nucleotide 573 to nucleotide 888 of the cDNA) in: 1 mM 
EDTA, 0.5 M NaHPO 4 pH 7.2, 7% SDS, 1% BSA, 50% formamide at 
42°C. The blot was washed under stringent conditions with 0.1 x SSC, 
0.1% SDS at 70°C and 80°C for 30 min each. 
For RT-PCR, total mRNA was extracted, extensively treated with 
DNAse I and reverse transcribed into cDNA as described [23]. All 
RNAs were tested for genomic contamination by RT-PCRs in which 
the reverse transcriptase was omitted (data not shown). To determine 
the expression pattern of the cloned enzyme, two oligonucleotides, PE 
3 and PE 4, were used which detect specifically transcripts for hPDE 
IV-C and hPDE IV-A, but not for PDE IV-B or PDE IV-D. PCR 
reactions were performed in 50 ¢tl in the presence of 1 pCi [~-nP]dCTP 
and 10 pmol each of the primers PE 3 and PE 4. Taq-DNA polymerase 
was purchased from Boehringer-Mannheim. After restriction with 
EeoRV which cuts specifically in the hPDE IV-C cDNA, or BstXI 
which digests only PCR fragments derived from hPDE IV-A cDNA, 
the DNA fragments were separated on 4% agarose gels. The gels were 
dried and exposed to X-ray films (Kodak). 
2.4. PDE expression assay" 
The cDNA was cloned into the extrachromosomal pYEMS2 yeast 
expression vector (M. Sullivan, unpublished), pYEMS2 contains the 
ura3 gene as selectable marker and a cassette containing the constitu- 
tively expressing glyceraldehyde-3-phosphate d hydrogenase (GPD-) 
promotor and 3-phosphoglycerate kinase (PGK-) terminator spaced by 
a multiple cloning site. The hPDE IV-C cDNA was ligated into the 
BamHIlSall restriction sites behind the GPD promotor. This construct, 
pYPDE-IVC, was transformed into the PDE deficient yeast strain 
YMS5. Both PDE genes in this yeast strain had previously been inter- 
rupted by inserting the selection markers LYS2 and LEU2 into the 
coding sequences of the yeast PDE 1 and PDE 2 genes, similar to the 
strains described by McHale et al. [21]. Although PDE deficient yeast 
strains grow normally under standard conditions, they are more sensi- 
tive to heat shock (3 min, 55°C). Yeast transformants expressing an 
exogenous functional PDE IV gene reveal normal growth and heat 
shock resistance [3,24]. 
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TTC ACT CAT ACC CAG TTT TGT TTC TGA AAC TAC GGT AGG GC4~ CAG GAA GAG GAG CAG AAA AGA AGG GCT GGG CAA GGC ATA GTG 2871 
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CAC TTG AAT TCA GGA GGT GGA GGT TGC AGT GAG CCG ACA TCA TGC CAC TGC ACT CCA GCC TGG GGC TGA CAG AGC AAG ACA CTG 3465 
AAA AAA AAA AAA AAA 3495 
amino acid sequence of hPDE IV-C. Amino acids below various symbols correspond to motifs for phosphorylation 
kinase; * = protein kinase C; • = casein II protein kinase) which may be important in the regulation of enzyme 
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Fig. 2. Alignment of the deduced human PDE IV-C amino acid sequence with the three other full-length human PDE IV amino acid sequences (PDE 
46, TM72, PDE43 [17]) and the previously described partial rat rPDE IV-C [26] and human (PDE21[17]) PDEIV-C sequences. The conserved catalytic 
and N-terminal UCR 1 and UCR 2 motifs are indicated. 
2.5. Enzyme isolation and pharmacological nalysis 
Pelleted yeast (5 ml) was suspended in 50 ml of buffer (10 mM 
tris-hydroxymethyl-aminomethane, 1 mM ethylenediamine-tetraacetic 
acid, 1 pg/ml each of leupeptin and pepstatin A, 175 pg/ml phen- 
ylmethyl-sulphonyl fluoride, 1 mM dithiothreitol, pH 7.4 with HCI). 
After centrifugation, 15 g of glass beads (425-600 ,urn, acid-washed; 
Sigma) washed with buffer were added to the pellet. The slurry contain- 
ing the glass beads was vigorously agitated for 4 h at 4°C after the 
addition of 1 ml of buffer and 60 mg of cholamidopropane sulphonic 
acid were added to the slurry. Disintegration of the yeast cells, usually 
>50%, was observed by phase-contrast microscopy. The slurry was 
subsequently transferred to a coarse glass funnel, collected by suction 
and washed with a total of 15 ml buffer. The flow-through was sepa- 
rated by centrifugation (2000 x g, 10 min, 4°C). The pellet was resus- 
pended in 15 ml of buffer. PDE activity was determined in this suspen- 
sion and in the cytosolic supernatant. 
The assay protocol was based on the two-step method described by 
Thompson et al. [25] modified for 96-well microtitre plates. Briefly, 
enzyme was diluted with homogenization buffer (see above) such that 
10-30% total substrate hydrolysis was obtained during the assay. To 
start the reaction, 25/11 of diluted enzyme was added to 100 ,ul of 
substrate ([3H]cAMP, 1.25 pM, 740 Bq). After 30 min at 37°C, the 
reaction was stopped in a hot water bath (65°C, 5 min). Plates were 
cooled on ice and incubated for 10 min at 37°C with 25 ~1 of nucleoti- 
dase (0.1 mg/ml in water; snake venom from Oiophaghus hannah). The 
unreacted substrate was separated from [3H]adenosine by sequentially 
adding aliquots (100 + 50 + 50 ,ul, at 5 min intervals) of 30% (v/v) 
Dowex 1 x 2 slurry (acetate form) in 0.2% (v/v) acetic acid. The Dowex 
and the bound cAMP was pelleted by centrifugation (150 x g, 5 min). 
Aliquots of the supernatants were transferred onto 96-well, solid-phase 
scintillation plates (LumaPlate, Canberra Packard) using an automated 
pipetting device (Hamilton MicroLab 2200), dried for > 4 h at 60 ° C, 
and counted (Canberra Packard TopCount). Concentration-inhibition 
curves were established using graded inhibitor concentrations in pres- 
ence of constant solvent concentrations (50 ,ul DMSO/ml final assay 
mixture). ICs0 values were estimated using non-linear least squares 
fitting to the two-parameter logistic equation (MicroCal ORIGIN). 
3. Results 
3.1. Cloning of a PDE type IV isogene from human substantia 
r l ig ra  
Screening of  three mill ion independent clones of  a commer- 
cial 2-Zap cDNA library from human substantia nigra with a 
PDE IV-specific ol igonucleotide revealed one clone with an 
insert size of  450 bp. Sequence analysis showed highest homol- 
ogy to the partially cloned rat PDE IV-C isogene. RT-PCR 
analysis of  various cell lines displayed that this human isogene 
is expressed in neuroblastoma SH-SY5Y cells. To obtain the 
5' and 3' ends of  the isolated gene, we screened a cDNA library 
derived from SH-SY5Y cells. A l though we isolated a 3 kb 
cDNA clone, no in-frame stop codon was present at the 5' end. 
The complete open reading frame was then obtained after two 
sequential inverse PCR steps with SH-SY5Y cDNA.  The frag- 
ments of  the 5'-end obtained by this procedure were combined 
with the 3 kb clone, finally resulting in a 3495 bp cDNA clone 
with an in-frame 5' stop signal (Fig. 1). The sequence contained 
a complete open reading frame of  2136 bp corresponding to a 
protein of  712 amino acids (Fig. 1). Nucleotide comparisons 
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Fig. 3. Heat shock assay for functional hPDE IV-C expression i yeast. 
A/C -- PDE deficient yeast containing pYEMS IV-C without/with heat 
shock; B/D = PDE deficient yeast without/with heat shock. Cells were 
grown after the heat shock (3 min, 55°C) for 16 h at 30°C in 1 ml of 
liquid medium. 2/21 were then plated on agar medium and incubated 
for 18 h at 30°C. 
with the rat and human PDE IV genes howed highest homol- 
ogy between this cDNA and the rat PDE IV-C partial clone of 
1736 bp [26]. While this work was in progress, ahuman cDNA 
fragment of 1155 bp identical with the 3' part of the catalytic 
region of this PDE-type was described [17]. The amino acid 
sequence deduced from our clone displayed 82.9% overall se- 
quence identity to the rat PDE IV-C [26,27], 73.2% to hPDE 
IV-A, 67.5% to hPDE IV-B and 72.8% to hPDE IV-D [17], 
respectively. Therefore we suggest that the clone represents he 
human homologue of the rat PDE IV-C. The human IV-C 
cDNA contains two conserved regions, UCR 1 and UCR2, also 
found upstream of the catalytic domain in all other cloned 
human PDE IV isogenes. The sequence contains two consensus 
sequences for cAMP-dependent protein kinase, one each in the 
UCR1 region and the catalytic domain and several consensus 
motifs for protein kinase C and casein kinase II. An alignment 
of the four human PDE IV isoforms and the rat PDE IV-C 
isoform sequences are depicted in Fig. 2. 
3.2. Functional and pharmacological characterization of the 
PDE IV-C isoenzyme 
The human PDE IV-C was introduced into a yeast strain 
lacking endogenous PDE activity. PDE deficient yeast is sensi- 
tive to heat shock because of an inhibition of cell proliferation 
by increased cAMP levels formed due to the activation of 
adenylate cyclase during heat shock. The exogenous PDE IV-C 
gene restores the heat shock resistance of the yeast cells (Fig. 
3) by reducing the elevated level of cAMP [24]. 
The recombinant hPDE IV-C protein was partially purified 
from the expressing yeast and assayed for cAMP hydrolysis 
activity and sensitivity to PDE IV specific inhibitors. As shown 
in Fig. 4, the recombinant protein showed a Km of 1.5 + 0.3 pM 
for cAMP hydrolysis and a relative Vmax of 37 + 5.2 nmol/min/ 
mg (mean + S.E.M. from 5 experiments) (Fig. 4a). The rank 
order of potency for PDE inhibitors was Rolipram > 
Denbufylline>Ro 20-1724 > IBMX (3-Isobutyl-l-methylxan- 
a) b) 
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Fig. 4. Pharmacological analysis. (a) Kinetic analysis of the hydrolysis of [3H]cAMP from supernatant i  yeast extracts containing the recombinant 
hPDE IV-C enzyme. Km and Vma xvalues were determined bystandard methods (five measurements for each data point, presented asmean + S.E.M.). 
The straight line of the Liueweawer-Burk plot (inset) indicates simple Michaelis-Menten-type kinetics. (b) Effect of different inhibitors on enzyme 
activity in extracts from yeast ceils containing the recombinant hPDE IV-C. Curve fitting was performed under the assumption that excessive 
concentrations of inhibitors completely block the enzyme. 
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Fig. 5. Tissue distribution of hPDEIV-C. (a) Northern blot analysis was performed with 2 ,ug of poly(A) ÷ RNA from various human tissues. A hPDE 
IV-C specific probe was used. (b) RT-PCR comparison ofthe two hPDE IV isoforms A and C in different tissues and cell lines. The PCR products 
(440 bp) obtained with the primer pair PE3/PE4 were cleaved with either BstXI or EcoRV to distinguish between the two hPDE IV isogenes A and 
C. BstXI cleaved specifically inthe PCR fragments derived from the hPDE IV-A cDNA (330 bp + 110 bp), EcoRV cleaved PCR fragments amplified 
from hPDE IV-C cDNA (345 bp + 95 bp). 
thine) with ICs0 of 6.6 + 0.6, 14.6 + 3.1, 19.6 + 1.4 and 
36.2 + 2.8/zM, respectively (Fig. 4b). 
3.3. Tissue distribution of  the human PDE IV-C 
PDE IV distribution was determined by Northern blot hy- 
bridization (Fig. 5a) and reverse polymerase chain reaction 
(RT-PCR; Fig. 5b). Northern blot analysis of RNAs isolated 
from human tissues revealed a major band of 4.2 kb in all 
tissues and a minor band of 5.7 kb present only in heart and 
skeletal muscle (Fig. 5a). A very weak PDE IV-C signal was 
observed in lung. Various human tissues and cell lines were also 
tested by RT-PCR demonstrating that the PDE IV cDNA was 
detectable in all tissues analyzed with the exception of blood 
(Fig. 5b). It is particularly interesting that in different cell types 
of the immune system like lymphocytes oreosinophils we could 
not observe a specific signal. In the tested human euronal cell 
lines SH-SY5Y (Fig. 5b) and SH-N SH (data not shown) we 
found a specific restriction of the PCR fragment with EcoRV 
indicating the expression of hPDE IV-C in this cells. 
4. Discussion 
We have isolated a full-length cDNA clone for the human 
phosphodiesterase type IV-C isoform (PDE IV-C) from sub- 
stantia nigra and SH-SY5Y cell libraries. Pharmacological 
analysis of the recombinant enzyme xpressed inyeast revealed 
that the hPDE IV-C enzyme has typical PDE IV characteristics 
[17,24] like low K m cAMP hydrolysis (1.5/zM) and rolipram 
sensitivity (ICs0 = 6.6/tM). The pharmacological properties of 
the recombinant hPDE IV-C showed small differences com- 
pared to other known human PDE IV isoforms 
[15,16,17,28,29]. hPDE IV-A, B and D showed higher Kms (18, 
8 and 7.2 pM, respectively) but lower rolipram sensitivities with 
ICs0 of 0.5, 0.4 and 0.18/IM, respectively. 
The amino acid sequence contains all conserved motifs de- 
scribed for PDE IV isoforms [17]. The catalytic domain is more 
than 80% homologous to those of the other human PDE IV 
enzymes. Upstream of this catalytic domain, two conserved 
domains with unknown functions, UCR1 and UCR2 
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(UCR = upstream conserved region), have been described. Re- 
cently it has been reported that one of the rat PDE IV isoforms 
(rPDE IV-D) is rapidly activated by cAMP-dependent phos- 
phorylation even in the absence of protein synthesis [30]. The 
presence of a cAMP-dependent protein kinase phosphorylation 
motif in UCR1 suggests that this region may be involved in 
short-term regulation of PDE IV activity. This requires addi- 
tional analysis, however, since a further PKA site is present in 
the catalytic domain. 
Genomic analysis revealed that hPDE IV-C is encoded by a 
single copy gene (data not shown). The previously published 
partial human PDE IV-C sequence was mapped to human 
chromosome 19 [31]. Northern blotting indicated the presence 
of a 4.2 kb RNA in all tissues and a tissue-specific o currence 
of an additional 5.7 kb RNA. This RNA may be produced by 
differential splicing or alternative use of polyadenylation sites 
or promoters. Differential RNA splicing has been described for 
other at and human PDE IV isoforms [17,27,28,32]. It has been 
reported for the rat PDE IV-A (RD1) gene that splice variants 
direct the enzyme to distinct subcellular localizations. A short 
leader sequence in the N-terminus of the rat PDE IV-A directs 
the enzyme to the membrane [6]. Further investigation will 
elucidate if the 5.7 kb RNA serves a similar function. 
The hPDE IV-C tissue distribution analysis revealed a dis- 
tinct but overlapping pattern compared to other isoforms 
[17,18]. In contrast to the hPDE IV-A, -B and -D, hPDE IV-C 
is absent in cells of the immune system [18]. We found expres- 
sion of the human PDE IV-C isogene mRNA in total brain and 
in substantia nigra. Surprisingly, it is almost absent in these 
regions of the rat brain [18,33]. This difference between rat and 
human may indeed be caused by species-specific expression 
patterns. It could, however, also be explained if another, as yet 
unknown rat PDE IV isogene homologous to the human PDE 
IV enzyme described here existed. There is, however, no exper- 
imental evidence of yet another isoform. 
The use of recombinant proteins will be useful to find 
isoform specific inhibitors which will help to assign the various 
physiological functions of PDE IV to specific enzyme subtypes. 
For medical use, subtype-specific inhibitors may reduce possi- 
ble undesirable side effects occurring with unselective PDE IV 
inhibitors like rolipram and may be helpful for the treatment 
of CNS diseases like depression or Parkinson's disease or pe- 
ripheral diseases like asthma or atopic dermatitis. 
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